# A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber

> **NCT00848965** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 59 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial
- Allergic Rhinitis

## Interventions

- **DRUG:** Fluticasone propionate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00848965
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848965, "A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00848965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*